Tesh Khullar: Biosimilar Education in Oncology

Transcript

I think education around what biosimilars actually are. So, the physicians I talked to give me a great analogy that they're using biosimilars right now; because of the way these monoclonal antibodies are made, one batch of Rituxan is different right now then a batch of Rituxan, you know, made 2 years ago. So essentially you're using a biosimilar right now and as long as there's a cost incentive to use cheaper therapies, I think the consumers are going to look at it just like you look at generics. That’s what I believe is going to happen.